keyword
MENU ▼
Read by QxMD icon Read
search

Vaccination against HPV

keyword
https://www.readbyqxmd.com/read/28644153/louisiana-physicians-are-increasing-hpv-vaccination-rates
#1
Donna L Williams, Courtney S Wheeler, Michelle Lawrence, Stacy S Hall, Michael Hagensee
Human papilloma virus (HPV) is a common virus that can cause genital warts and certain cancers. The HPV vaccine is effective in preventing many HPV-associated diseases, however, vaccination rates suggest many remain unprotected. This study examined successful strategies used by physicians to improve HPV vaccination rates. Providers with above average vaccination rates were identified. A representative from each provider participated in an interview to identify strategies used to boost HPV vaccination. Key strategies in ensuring vaccine completion were reminders, education, standing orders, and scheduling future vaccine appointments at time of first dose...
May 2017: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
https://www.readbyqxmd.com/read/28641366/human-papillomavirus-vaccine-dose-effectiveness-against-incident-genital-warts-in-a-cohort-of-insured-us-females
#2
Susan Hariri, Megan S Schuler, Allison L Naleway, Matthew F Daley, Sheila Weinmann, Bradley Crane, Sophia R Newcomer, Dennis Tolsma, Lauri E Markowitz
We examined effectiveness of HPV vaccination by dose number and interval against incident genital warts in a cohort of 64,517 females in the United States during 8/2006-9/2012. Eligible females were classified into 0, 1-dose, 2-dose < 6 months apart, 2-dose ≥6 months apart, and 3-dose groups and followed until genital wart diagnosis, loss to follow-up, or end of study. Propensity score weights were used to balance baseline differences across groups. To account for latent genital warts before vaccination, 6-month and 12-month buffer periods from last and first vaccine dose, respectively, were applied...
June 21, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28633892/seropositivity-to-non-vaccine-incorporated-genotypes-induced-by-the-bivalent-and-quadrivalent-hpv-vaccines-a-systematic-review-and-meta-analysis
#3
Sara L Bissett, Anna Godi, Mark Jit, Simon Beddows
BACKGROUND: Human papillomavirus vaccines have demonstrated remarkable efficacy against persistent infection and disease associated with vaccine-incorporated genotypes and a degree of efficacy against some genetically related, non-vaccine-incorporated genotypes. The vaccines differ in the extent of cross-protection against these non-vaccine genotypes. Data supporting the role for neutralizing antibodies as a correlate or surrogate of cross-protection are lacking, as is a robust assessment of the seroconversion rates against these non-vaccine genotypes...
June 17, 2017: Vaccine
https://www.readbyqxmd.com/read/28622401/impact-of-a-pharmacist-conducted-educational-program-on-human-papilloma-virus-vaccination-rates-in-a-low-socioeconomic-population-in-the-city-of-lares-pr
#4
Edda Marie Jiménez-Quiñones, Kyle Melin, Francisco Javier Jiménez-Ramírez
OBJECTIVE: To observe whether local vaccination rates are improved by a patient and physician education program on the human papillomavirus (HPV) vaccine in Farmacia San José, Lares. According to the Puerto Rico Immunization Registry, the HPV vaccine is currently underutilized. METHODS: Patients within the ages of 18 and 26 years who are current patients of Farmacia San José were contacted by phone and approached in person at the pharmacy. Once contacted, patients were provided with educational materials and counseling regarding the risks and benefits of HPV vaccination...
June 2017: Puerto Rico Health Sciences Journal
https://www.readbyqxmd.com/read/28610824/safety-and-perception-what-are-the-greatest-enemies-of-hpv-vaccination-programmes
#5
Paolo Bonanni, Beatrice Zanella, Francesca Santomauro, Chiara Lorini, Angela Bechini, Sara Boccalini
Vaccines stimulate a person's immune system to produce an adequate reaction against a specific infectious agent; i.e. the person is protected from that disease without having to get it first. As vaccines are administrated to healthy subjects, they are held to the highest standards of safety. Regarding human papillomavirus (HPV) vaccines, at present three prophylactic vaccines are licensed (bivalent HPV 16/18, quadrivalent HPV 6/11/16/18 and the nonovalent HPV 6/11/16/18/31/33/45/52/58 vaccine). Pre- and post-licensure studies (i...
June 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28600369/timing-of-two-versus-three-doses-of-quadrivalent-hpv-vaccine-and-associated-effectiveness-against-condyloma-in-sweden-a-nationwide-cohort-study
#6
Lamb F, Herweijer E, Ploner A, Uhnoo I, Sundström K, Sparén P, Arnheim-Dahlström L
OBJECTIVE: To assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years. DESIGN: Register-based nationwide open cohort study. SETTING: Sweden. PARTICIPANTS: Girls and women initiating qHPV vaccination before age 20 years between 2006 and 2012. The study cohort included 264 498 girls, of whom 72 042 had received two doses of qHPV vaccine and 185 456 had received all three doses...
June 8, 2017: BMJ Open
https://www.readbyqxmd.com/read/28599844/somatoform-and-neurocognitive-syndromes-after-hpv-immunization-are-not-associated-to-cell-mediated-hypersensitivity-to-aluminum
#7
Dimitri Poddighe, Maria Vadalà, Carmen Laurino, Beniaminoi Palmieri
Vaccines against human papilloma virus (HPV) have been demonstrated to be very effective to prevent infection-related neoplasms. However, several reports describing heterogeneous post-vaccination phenomena have been published in last few years. The spectrum of these disorders includes both immune-mediated neurological diseases and neuropsychiatric functional disorders. Some researchers speculated about a genetic predisposition, but others hypothesized a role of adjuvants, including some metals and, particularly, aluminum...
June 6, 2017: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/28596091/human-papillomavirus-vaccines-who-position-paper-may-2017-recommendations
#8
(no author information available yet)
This article presents the World Health Organization's (WHO) recommendations on the use of human papillomavirus (HPV) vaccines excerpted from the WHO position paper on Human papillomavirus vaccines: WHO position paper, May 2017, published in the Weekly Epidemiological Record [1]. This position paper replaces the 2014 WHO position paper on HPV vaccines [2]. The position paper focuses primarily on the prevention of cervical cancer, but also considers the broader spectrum of cancers and other diseases preventable by HPV vaccination...
June 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28595031/factors-associated-with-parents-intent-to-vaccinate-adolescents-for-human-papillomavirus-findings-from-the-2014-national-immunization-survey-teen
#9
Kahee A Mohammed, Elaina Vivian, Travis M Loux, Lauren D Arnold
INTRODUCTION: While factors associated with receipt of human papillomavirus (HPV) vaccination have been well characterized, less is known about the characteristics associated with parents' intent to have their adolescent children vaccinated. This study aimed to examine factors associated with parental intention toward HPV vaccination. METHODS: We analyzed data on 10,354 adolescents aged 13 to 17 years from the 2014 National Immunization Survey-Teen. Weighted multivariable logistic regression was used to examine associations between sociodemographic characteristics of mothers and adolescents, as well as a health care provider recommendation with parents' intention to have their children receive HPV vaccine...
June 8, 2017: Preventing Chronic Disease
https://www.readbyqxmd.com/read/28594305/potential-impact-of-a-nonavalent-hpv-vaccine-on-hpv-related-low-and-high-grade-cervical-intraepithelial-lesions-a-referral-hospital-based-study-in-sicily
#10
Giuseppina Capra, Lucia Giovannelli, Domenica Matranga, Carmelina Bellavia, Maria Francesca Guarneri, Teresa Fasciana, Giovanna Scaduto, Alberto Firenze, Alessandra Vassiliadis, Antonio Perino
While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy)...
June 8, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28591548/uk-healthcare-professionals
#11
Tom Nadarzynski, Carrie Llewellyn, Daniel Richardson, Alex Pollard, Helen Smith
Background: Female-only human papillomavirus (HPV) vaccination will fail to protect men who have sex with men (MSM) against HPV and its sequelae (i.e. genital warts and anal cancers). In the absence of gender-neutral HPV vaccination, targeted vaccination at sexual health clinics for MSM offers a valuable preventive opportunity. This study aimed to identify sexual healthcare professionals' (HCPs) perceived barriers and facilitators for MSM-targeted HPV vaccination. Methods: Nineteen telephone interviews with UK-based self-referred HCPs (13 doctors, three nurses, three health advisers) were conducted in October and November 2014...
June 8, 2017: Sexual Health
https://www.readbyqxmd.com/read/28584449/epitope-design-of-l1-protein-for-vaccine-production-against-human-papilloma-virus-types-16-and-18
#12
Sunanda Baidya, Rasel Das, Md Golam Kabir, Md Arifuzzaman
Cervical cancer accounts for about two-thirds of all cancer cases linked etiologically to Human Papilloma Virus (HPV). 15 oncogenic HPV types can cause cervical cancer, of which HPV16 and HPV18 combinedly account for about 70% of it. So, effective epitope design for the clinically relevant HPV types 16 and 18 would be of major medical benefit. Here, a comprehensive analysis is carried out to predict the epitopes against HPV types 16 and 18 through "reverse vaccinology" approach. We attempted to identify the evolutionarily conserved regions of major capsid protein (L1) as well as minor capsid protein (L2) of HPV and designed epitopes within these regions...
2017: Bioinformation
https://www.readbyqxmd.com/read/28553758/hpv-vaccine-acceptance-among-african-american-mothers-and-their-daughters-an-inquiry-grounded-in-culture
#13
Kayoll V Galbraith-Gyan, Julia Lechuga, Coretta M Jenerette, Mary H Palmer, Angelo D Moore, Jill B Hamilton
BACKGROUND: Much of the research on African-Americans' HPV vaccine acceptance has largely focused on racial/ethnic differences related to cognitive, socio-economical, and structural factors that contribute to differences in HPV vaccine acceptance and completion. A growing body of literature suggest that cultural factors, such as mistrust of healthcare providers (HCPs) and the healthcare system, religion, and social norms related to appropriate sexual behaviors, also plays a prominent role in their HPV vaccine acceptance...
May 29, 2017: Ethnicity & Health
https://www.readbyqxmd.com/read/28549940/-human-papillomavirus-nonavalent-vaccine-update-2017
#14
F X Bosch, D Moreno, E Redondo, A Torné
Human papillomavirus (HPV) is the causative agent of 5% of human cancers. HPV infection is necessary for the development of cervical cancer and is responsible of a variable percentage of cancers of anus, vulva, vagina, penis, and oropharynx. Since 2007, 2 vaccines against HPV have been commercially available in Spain: bivalent (HPV types 16/18), and tetravalent (HPV types 6/11/16/18). In order to extend the protection afforded by HPV vaccines, a clinical program was launched in 2006 for the new nonavalent vaccine, including 9 HPV types (6/11/16/18/31/33/45/52/58)...
May 23, 2017: Semergen
https://www.readbyqxmd.com/read/28531261/age-of-acquiring-causal-human-papillomavirus-hpv-infections-leveraging-simulation-models-to-explore-the-natural-history-of-hpv-induced-cervical-cancer
#15
Emily A Burger, Jane J Kim, Stephen Sy, Philip E Castle
Background.: Although new human papillomavirus (HPV) infections can occur at all ages, the age at which women acquire their "causal" HPV infection that develops into cervical cancer is poorly understood and practically unobservable. We aimed to estimate the age distribution at which individuals acquired their causal HPV infection in the absence of HPV vaccination or screening to help guide the optimal use of both. Methods.: Using an empirically calibrated mathematical model that simulates the natural history of cervical cancer, we estimated the cumulative number of causal HPV infections by age, stratified by HPV genotype (HPV16 vs...
May 20, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28528686/hpv-entry-into-cells
#16
REVIEW
Pinar Aksoy, Elinor Y Gottschalk, Patricio I Meneses
Human papillomavirus (HPV) is a sexually transmitted virus responsible for the development of cervical cancer, anal cancer, head and throat cancers, as well as genital area warts. A major focus of current HPV research is on preventing the virus from entering a cell and transferring its genetic material to the nucleus, thus potentially preventing the development of cancer. Although the available HPV vaccines are extremely successful, approximately 15 additional cancer-causing HPVs have been identified that the vaccines do not protect against...
April 2017: Mutation Research
https://www.readbyqxmd.com/read/28526738/hpv-vaccine-slashes-rates-of-oral-infection
#17
(no author information available yet)
Vaccination against human papillomavirus (HPV) reduces the prevalence of oral infection by an estimated 88% among young adults in the United States, a protection that could help reduce rates of HPV-related oropharyngeal cancers, according to data that will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. However, the population-level benefit will remain low unless more people get vaccinated.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526331/prevalence-of-oral-human-papillomavirus-by-vaccination-status-among-young-adults-18-30years-old
#18
Jacqueline M Hirth, Mihyun Chang, Vicente A Resto
BACKGROUND: Although there is evidence that human papillomavirus (HPV) vaccination may protect against oral HPV infection, no current research has demonstrated this in the general population. METHODS: We used repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014. Participants 18-30years who indicated whether they had received the HPV vaccine and provided an adequate oral sample were included (N=3040)...
May 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28515303/spontaneous-and-vaccine-induced-clearance-of-mus-musculus-papillomavirus-type-1-mmupv1-muspv1-infection
#19
Rosie T Jiang, Joshua W Wang, Shiwen Peng, Tsui-Chin Huang, Chenguang Wang, Fabiana Cannella, Yung-Nien Chang, Raphael P Viscidi, Simon R A Best, Chien-Fu Hung, Richard B S Roden
Mus musculus Papillomavirus1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not common laboratory strains. To facilitate study of immune control, we sought an outbred and immune competent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) by scarification on their tail with MmuPV1 resulted in three clinical outcomes: 1) persistent (>2 months) papillomas (∼20%), 2) transient papillomas that spontaneously regress typically within 2 months (∼15%), 3) no visible papillomas and viral clearance (∼65%)...
May 17, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28499554/effectiveness-of-hpv-vaccines-against-genital-warts-in-women-from-valencia-spain
#20
Esther Navarro-Illana, Mónica López-Lacort, Pedro Navarro-Illana, Juan José Vilata, Javier Diez-Domingo
OBJECTIVES: To assess the effectiveness of the HPV vaccines in preventing genital warts in young women. DESIGN: Population-based study using health databases. SETTING: Valencian Community (Spain). PARTICIPANTS: All girls and women aged 14-19years who were registered in the Valencian Community between January 2009 and December 2014 (n=279,787). MAIN OUTCOME MEASURES: Incident cases of genital warts were defined as the first activation of diagnosis code ICD-9-CM 078...
June 5, 2017: Vaccine
keyword
keyword
38921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"